We’re excited to share episode 2 of the Antibodies! podcast, recorded live at the Antibody Engineering & Therapeutics conference in San Diego.
Host Dr. Jonathan Davis PhD (Founder, Creative Antibodies) sits down with John Desjarlais PhD, Chief Scientific Officer at Xencor, to discuss learnings from two decades of antibody engineering: Fc platforms, T-cell engagers in solid tumors, and bispecifics in autoimmune disease.
In this conversation, they discuss:
How a classical trombonist ended up engineering some of the most widely used Fc platforms in antibody therapeutics
The KLH study that proved obexelimab could shut down B cells. Data so meaningful, John still keeps the plot on his office wall
Why target selectivity matters more than immune environment for T-cell engagers in solid tumors
The autoimmune gold rush: using T-cell engaging bispecifics to reset the immune system, inspired by Georg Schett’s CAR-T breakthrough
Trispecifics, AND-gate targeting, and where bispecifics can go beyond oncology
Be sure to listen all the way to the end for a surprise treat - an improvised harmonica blues duet between Jonathan and John!
Podden och tillhörande omslagsbild på den här sidan tillhör
The Antibody Society. Innehållet i podden är skapat av The Antibody Society och inte av,
eller tillsammans med, Poddtoppen.
